This map shows the geographic impact of WH Bakker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by WH Bakker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites WH Bakker more than expected).
This network shows the impact of papers produced by WH Bakker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by WH Bakker. The network helps show where WH Bakker may publish in the future.
Co-authorship network of co-authors of WH Bakker
This figure shows the co-authorship network connecting the top 25 collaborators of WH Bakker.
A scholar is included among the top collaborators of WH Bakker based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with WH Bakker. WH Bakker is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
All Works
16 of 16 papers shown
1.
Valkema, Roelf, François Jamar, Stanislas Pauwels, et al.. (2003). Phase 1 study of peptide receptor radionuclide therapy (PRRT) with [Y-90-DOTA,Tyr(3)]octreotide in patients with somatostatin receptor positive tumors. Cancer Biotherapy and Radiopharmaceuticals. 18(2). 295–295.7 indexed citations
2.
Valkema, Roelf, François Jamar, Stanislas Pauwels, et al.. (2002). Phase I study of therapy with Y-90-SMT487 (octreother) in patients with somatostatin receptor (SS-R) positive tumors.. Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)). 43(5).16 indexed citations
3.
Valkema, Roelf, Stanislas Pauwels, François Jamar, et al.. (2002). Peptide receptor radionuclide therapy (PRRT) with Y-90-DOTA(0),Tyr(3)-octreotide (Y-Oc) and In-111-DTPA(0)-octreotide (In-Oc): Comparison of tumor response and toxicity.. DIAL (Catholic University of Leuven). 43(5).4 indexed citations
4.
Valkema, Roelf, François Jamar, Stanislas Pauwels, et al.. (2001). Safety and efficacy of [Y-90-DOTA,Tyr(3)]-octreotide (Y-90-SMT487; OctreoTher) peptide receptor radionuclide therapy (PRRT). Preliminary results of a phase-1 study. European Journal of Nuclear Medicine and Molecular Imaging. 28(8). 1025–1025.10 indexed citations
5.
Valkema, Roelf, François Jamar, Stanislas Pauwels, et al.. (2000). Targeted radiotherapy with Y-90-DOTA-TYR3-octreotide (Y-90-SMT487; OctreoTher (TM)): A phase I study.. Digital Access to Libraries. 41(5).7 indexed citations
6.
Jamar, François, Stanislas Pauwels, Stéphan Walrand, et al.. (2000). Tumor dosimetry based on PET Y-86-DOTA-Tyr3-octreotide (SMT487) and CT-scan predicts tumor response to Y-90-SMT487 (OctreoTher (TM)) therapy.. Digital Access to Libraries. 41(5).7 indexed citations
Kooij, P.P.M., et al.. (1999). Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.. PubMed. 40(5). 762–7.90 indexed citations
10.
Krenning, E. P., Roelf Valkema, P.P.M. Kooij, et al.. (1999). Scintigraphy and radionuclide therapy with [indium-111-labelled-diethyl triamine penta-acetic acid-D-Phe1]-octreotide.. PubMed. 31 Suppl 2. S219–23.93 indexed citations
11.
Jong, M. de, WH Bakker, Leo J. Hofland, et al.. (1998). Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy.. PubMed. 58(3). 437–41.181 indexed citations
Krenning, E. P., WH Bakker, Marion de Jong, et al.. (1992). Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide.. PubMed. 33(5). 652–8.337 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.